AP306 BID

Phase 2Small molecule

AAlebund Pharmaceuticals

AP306 BID is one of 7 small molecule programs targeting Hyperphosphatemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperphosphatemiaRecruiting

HyperphosphatemiaPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Hyperphosphatemia

#DrugCompanyPhaseTrials

Niacor

AbbVie

Approved

2 2

Fosrenol

Takeda

Approved

1 3

TS-172

TTaisho Pharmaceutical Co., Ltd.

Phase 3

5 4

AP301

AAlebund Pharmaceuticals

Phase 3

2 5

AP306 BID

AAlebund Pharmaceuticals

Phase 2

1 6

Auryxia

KKeryx Biopharmaceuticals

Bixalomer

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Hyperphosphatemia

NCT06712654

Clinical

Trials by Indication[1]

Hyperphosphatemia1 trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis

Recruiting·AAlebund Pharmaceuticals·Phase 2·NCT06712654·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AP306 BID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AP306 BID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AP306 BID. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alebund Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlebund Pharmaceuticals

AP306 BID

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hyperphosphatemia1 trial

References

Drug Info

Quick Facts

Related News